Collectively, this study provides the first evidence that osimertinib induces ER stress-related paraptosis in GBM cells, reveals a TRIP13-driven resistance mechanism against osimeritinib, suggesting that the AKT inhibitor MK-2206 might overcome this resistance. The gene discussed is AKT1; the disease is glioblastoma.